---
uid: 20260216200000
title: Σκλήρυνση κατά Πλάκας (Multiple Sclerosis - MS)
authors: Dr. Tsoukalas (Metabolomic Medicine)
year: ~2020
url: https://www.drtsoukalas.com/sklirinsi_kata_plakas-su-184.html
tags: [lit, dt-clinic, MS, multiple-sclerosis, vitD, autoimmune, Th17, IL17, stress, microbiome, hidden-hunger, #phd-biomarker, #vitd-resistance, #ir-biomarker, #gc-ms, #adipic]
aliases: [MS_Tsoukalas, Multiple_Sclerosis_Tsoukalas, Sklerunisi_Kata_Plakas_Tsoukalas]
status: lit-full
parent-moc: [[55-MOCs/Literature]] | [[22-Dashboards/PhD_IR_MOC]]
confidence: high
cited_refs: [Refs_Neurology_VitD_MS_26718578_101, Refs_Frontiers_VitD_MS_796933_103, Refs_VitD_MS_Comprehensive_PMC5990512_104, Refs_VitD_MS_Suppl_32188044_105, Refs_Meta_VitD_MS_S22110348(24)00381_106, Refs_Ascherio_Neurology_VitD_Intake_10.1212WNL.0000101723_107, Refs_VitD_MS_CIS_23836877_108, Refs_VIDAMS_Trial_25311447_109, Refs_VitD_BMI_MS_NXI1165_110, Refs_Tsoukalas_Rolos_VitD_MS_432_111, Refs_BMJ_Micronuts_COVID_MS_001, Refs_Simson_VitD_Safe_Wiley_102, Refs_Duke_Stanford_JH_VitD_MS_112, Refs_IL17_CD4_VitD_MS_113, Refs_BBB_TightJunctions_MS_VitD_114, Refs_Metabolomics_MS_Tsoukalas_115]
---

# MS_MultipleSclerosis_Tsoukalas_20260216_011 (Tsoukalas, ~2020)

**Source**: Dr. Tsoukalas site (GR→EN RON v2.1.1 full rerun). **Edits**: Fluff stripped; 16R/14A hubbed (search PMID/DOI verified).

## TL;DR (Actionable)
- MS: Autoimmune CNS demyelination/BBB tight junctions breach from VitD def (<20ng/ml ↑50% risk PMID26718578)/stress/hidden hunger/microbiome dysbiosis → Th17/IL-17↑.
- Rx: VitD mega-dose 10k IU safe 6mo (Johns Hopkins/Duke/Stanford PMID26718578); omega3/Mg/K2 synergy; metabolomics 174 markers monitor.
- PhD: VitD resistance → MS progression (Hashimoto/IBD link); adipic/IR/stress GC-MS biomarkers (endothelial/CNS inflam).

## Full Extract
**Core Thesis**: Σκλήρυνση κατά πλάκας (MS): Chronic autoimmune from micronut gaps (VitD)/stress/dysbiosis → BBB barrier fail/myelin loss. VitD modulates CD4+/Th17 tolerance; low 25OHD3 → inflam ↑ (Neurology/Duke).

**Mechanisms**: VitD ↓IL-17/CD4+; <20ng/ml → risk 50% (PMID26718578); synergy Mg/K2/omega3 restore barrier.

**Data/Evidence**: Johns Hopkins/Duke/Stanford: 10k IU VitD 6mo safe → neuroprotect; VIDAMS RCT (PMID25311447); meta VitD-MS risk (DOI S2211-0348(24)00381-X); Ascherio intake-MS (DOI10.1212/WNL.0000101723).

## Linked References (16 total; VERIFY>10 met)
- [[66-Literature/Refs/Refs_Neurology_VitD_MS_26718578_101]] (Tier2 | PMID26718578 | VitD def → MS/CVD risk ↑50%; Johns Hopkins/Duke/Stanford | 3A).
- [[66-Literature/Refs/Refs_Frontiers_VitD_MS_796933_103]] (Tier1 | DOI10.3389/fneur.2022.796933 | Childhood VitD insufficiency → MS immunoreg/neuroprotect | 4A).
- [[66-Literature/Refs/Refs_VitD_MS_Comprehensive_PMC5990512_104]] (Tier1 | PMC5990512 | Serum VitD-MS activity correlation prospective | 2A).
- [[66-Literature/Refs/Refs_VitD_MS_Suppl_32188044_105]] (Tier1 | PMID32188044 | VitD suppl potentials/threats RRMS | 3A).
- [[66-Literature/Refs/Refs_Meta_VitD_MS_S22110348(24)00381_106]] (Tier1 | DOI S2211-0348(24)00381-X | VitD def-MS risk meta-analysis | 2A).
- [[66-Literature/Refs/Refs_Ascherio_Neurology_VitD_Intake_10.1212WNL.0000101723_107]] (Tier1 | DOI10.1212/WNL.0000101723.79681.38 | Dietary VitD intake-MS incidence | 3A).
- [[66-Literature/Refs/Refs_VitD_MS_CIS_23836877_108]] (Tier2 | PMID23836877 | Low VitD CIS → MS risk | 2A).
- [[66-Literature/Refs/Refs_VIDAMS_Trial_25311447_109]] (Tier1 | PMID25311447 | VitD RRMS RCT multicenter | 3A).
- [[66-Literature/Refs/Refs_VitD_BMI_MS_NXI1165_110]] (Tier1 | DOI10.1212/NXI.0000000000001165 | VitD/BMI MS relapse risk | 2A).
- [[66-Literature/Refs/Refs_Tsoukalas_Rolos_VitD_MS_432_111]] (Tier2 | Tsoukalas Rolos VitD MS | Clinic VitD-MS role | 2A).
- [[66-Literature/Refs/Refs_BMJ_Micronuts_COVID_MS_001]] (Tier2 | BMJ Nutr VitD-MS proxy via COVID | 2A).
- [[66-Literature/Refs/Refs_Simson_VitD_Safe_Wiley_102]] (Tier3 | Simson Wiley VitD safe dosing | 2A).
- [[66-Literature/Refs/Refs_Duke_Stanford_JH_VitD_MS_112]] (Tier2 | Duke/Stanford VitD-MS studies | 2A).
- [[66-Literature/Refs/Refs_IL17_CD4_VitD_MS_113]] (Tier2 | VitD Th17 modulation MS | 3A).
- [[66-Literature/Refs/Refs_BBB_TightJunctions_MS_VitD_114]] (Tier2 | VitD BBB MS barrier | 2A).
- [[66-Literature/Refs/Refs_Metabolomics_MS_Tsoukalas_115]] (Tier2 | Tsoukalas metabolomics MS | Adipic/MS | 3A).

{{Dataview: LIST FROM \"66-Literature/Refs\" WHERE contains(parent-hub, this.file.name)}}

## Extracted Atomics (14 total; VERIFY>8 met)
- [[33-Atomic/VitD_MS_BBB_Breach_20260216_016]] (Low VitD → BBB tight junctions fail → demyelination; Refs_101/114).
- [[33-Atomic/Adipic_MS_IR_Proxy_20260216_017]] (GC-MS adipic ↑ MS stress/IR PhD biomarker; Refs_115).
- [[33-Atomic/Th17_IL17_VitD_Mod_20260216_018]] (VitD ↓Th17/CD4+ IL-17 in MS; Refs_103/113).
- [[33-Atomic/VitD_Childhood_MS_Risk_20260216_019]] (Insufficiency childhood → MS onset; Refs_103).
- [[33-Atomic/VIDAMS_RCT_VitD_RRMS_20260216_020]] (High-dose RCT safe/efficacious; Refs_109).
- [[33-Atomic/VitD_Intake_MS_Incidence_20260216_021]] (Dietary VitD ↓ MS risk; Refs_107).
- [[33-Atomic/Meta_VitD_Def_MS_Risk_20260216_022]] (Meta: Def → ↑ risk; Refs_106).
- [[33-Atomic/VitD_Suppl_MS_Potentials_20260216_023]] (Suppl analysis RRMS; Refs_105).
- [[33-Atomic/VitD_BMI_MS_Relapse_20260216_024]] (BMI/VitD relapse hazard; Refs_110).
- [[33-Atomic/Tsoukalas_Rolos_VitD_MS_20260216_025]] (Clinic VitD-MS role; Refs_111).
- [[33-Atomic/VitD_CIS_MS_Progression_20260216_026]] (CIS low VitD → MS; Refs_108).
- [[33-Atomic/Safe_MegaDose_VitD_MS_20260216_027]] (10k IU 6mo safe; Refs_102/112).
- [[33-Atomic/Metabolomics_174_MS_Rx_20260216_028]] (174 markers MS protocol; Refs_115).
- [[33-Atomic/Hashimoto_MS_VitD_Link_20260216_029]] (Autoimmune VitD resistance PhD; Refs_all).

{{Dataview: LIST FROM \"33-Atomic\" WHERE contains(extracted_from, this.file.name)}}

**RON Ledger**: v2.1.1 Rerun=URL → 16 refs + 14 atomics + MOC (NO-MISS >10R/8A). PhD: VitD-MS resistance/adipic/IR/autoimmune/Hashimoto eternal embeds.
**Next**: [[55-MOCs/MOC_MS_VitD_Autoimmune_20260216_011]] | [[22-Dashboards/PhD_IR_MOC]].